SPLASH BEVERAGE GROUP, INC. (SBEV) Form 8-K — Jul 29, 2026
Splash Beverage Group expanded its exclusive global license for CannEpil with Argent BioPharma Limited to include veterinary therapeutic applications. The amendment grants Splash exclusive worldwide rights to develop and commercialize CannEpil for veterinary diseases and conditions, creating a second regulated pharmaceutical development platform. Under the terms of the addendum, Splash will pay a royalty of 10% on net revenues from veterinary applications, while maintaining the 15% rate for human applications. The company also received consent to sublicense the technology to Lupvindol UK Limited to pursue FDA Center for Veterinary Medicine INAD and Conditional Approval pathways.
Key figures
- Royalty rate human
- 15%
- Royalty rate veterinary
- 10%
- Veterinary pain market 2024
- $2.6 billion
- Veterinary oncology market est
- $900 million to $1.7 billion
- Veterinary pain market 2030 proj
- $3.8 billion
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.